Balanced news tone
News Sentiment
BDSX sentiment intelligence
Biodesix Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
61
Balanced news tone
45 relevant articles
News tone and price action are not far from neutral.
72/100 classification confidence.
directly relevant articles
high-authority source matches
-2.6% over one week, +42.2% over four weeks, trend active, and near fair-value range.
Biodesix Inc. (BDSX) Stock Price | Live Quotes & Charts | NASDAQ
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Primary event
Market update
72/100 classification
One-week reaction
-2.6%
Price reacting lower
Trend fit
Trend active
42.2% over four weeks
Fair value
0.3%
Near fair-value range
Sentiment Mix
Positive, neutral, negative
Positive
23
Neutral
22
Negative
0
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
timothysykes.com
Direct company coverage
Biodesix Inc. (BDSX) Stock Price | Live Quotes & Charts | NASDAQ
This page provides live stock quotes and charts for Biodesix Inc. (BDSX) on NASDAQ, showing its current price of $22.15 with no change. It indicates that there are currently no analyst ratings or earnings information available for the company. The page also features general tradi
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 09 Jul 2026 23:10
- Source
- timothysykes.com
MarketBeat
Direct company coverage
AIGH Capital Management LLC Buys Shares of 758,328 Biodesix, Inc. $BDSX
AIGH Capital Management LLC has acquired 758,328 shares of Biodesix, Inc. (NASDAQ:BDSX) worth approximately $11.0 million, representing 7.5% of the company and 1.5% of AIGH's portfolio. Institutional investors collectively own 20.96% of Biodesix, with several hedge funds and asse
- Tone
- Positive 75/100
- Event
- Market update
- Published
- 09 Jul 2026 07:39
- Source
- MarketBeat
Stock Titan
Direct company coverage
Biodesix (BDSX) chair converts 1,361 RSUs and updates holdings
John Patience, a director and chairman of Biodesix Inc. (BDSX), reported a routine equity compensation transaction where 1,361 restricted stock units (RSUs) converted into common shares on June 30, 2026, increasing his direct holdings to 25,383 shares. He also retains 2,721 RSUs,
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 Jul 2026 20:40
- Source
- Stock Titan
www.marketscreener.com
Direct company coverage
Biodesix, Inc.(NasdaqGM: BDSX) added to Russell Microcap Value Benchmark Index
Biodesix, Inc. (NasdaqGM: BDSX) has been added to the Russell Microcap Value Benchmark Index. This inclusion highlights the company's position within the microcap market segment. The article also provides recent analyst ratings and company news, including earnings reports and cli
- Tone
- Positive 71/100
- Event
- Earnings
- Published
- 29 Jun 2026 13:40
- Source
- www.marketscreener.com
www.marketscreener.com
Direct company coverage
Biodesix, Inc.(NasdaqGM: BDSX) added to Russell Microcap Growth Benchmark Index
Biodesix, Inc. (NasdaqGM: BDSX), a diagnostic solutions company specializing in lung diagnostic testing and development services, has been added to the Russell Microcap Growth Benchmark Index. This inclusion highlights the company's growth potential and makes it eligible for a br
- Tone
- Positive 70/100
- Event
- Market update
- Published
- 29 Jun 2026 12:40
- Source
- www.marketscreener.com
TradingView
Direct company coverage
Enterprise value to revenue forward of Biodesix, Inc. – NASDAQ:BDSX
The article provides financial information for Biodesix, Inc. (NASDAQ: BDSX), specifically focusing on its enterprise value to revenue forward metric. It details where to find this data within the TradingView platform, alongside other financial overviews.
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 27 Jun 2026 23:09
- Source
- TradingView
TradingView
Direct company coverage
Biodesix, Inc. Actuals & Estimates (NASDAQ:BDSX)
This article provides an overview of Biodesix, Inc. (NASDAQ:BDSX) stock, including its current price, historical performance, analyst forecasts, and financial data. It highlights the company's recent earnings surprise, revenue figures, market capitalization, and upcoming earnings
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 27 Jun 2026 00:39
- Source
- TradingView
Simply Wall St.
Direct company coverage
Biodesix (BDSX) Stock Gets Fair Value Bump As Analysts Back Growth Path
- Tone
- Positive 58/100
- Event
- Market update
- Published
- 26 Jun 2026 19:07
- Source
- Simply Wall St.
TradingView
Direct company coverage
Biodesix, Inc. Actuals & Estimates (BOATS:BDSX)
This article provides an overview of Biodesix, Inc. (BDSX) including its financial actuals and estimates, stock forecast, historical prices, and upcoming earnings dates. It also details the company's recent earnings, revenue, net income, and EBITDA, along with information about i
- Tone
- Positive 64/100
- Event
- Earnings
- Published
- 26 Jun 2026 15:09
- Source
- TradingView
TradingView
Direct company coverage
Price to earnings forward of Biodesix, Inc. – NASDAQ:BDSX
The article provides financial information for Biodesix, Inc. (NASDAQ: BDSX), focusing on its forward price-to-earnings ratio. It is presented in the context of TradingView's market data offerings and includes various disclaimers regarding the data sources and copyright. The cont
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 26 Jun 2026 12:10
- Source
- TradingView
TradingView
Direct company coverage
BDSX Forecast — Price Target — Prediction for 2027
This article provides a detailed forecast for Biodesix, Inc. (BDSX), including analyst price targets, historical stock performance, and financial data. It highlights the current stock price, volatility, market capitalization, and upcoming earnings report, offering a comprehensive
- Tone
- Positive 82/100
- Event
- Analyst action
- Published
- 26 Jun 2026 08:10
- Source
- TradingView
marketscreener.com
Direct company coverage
Roth Capital Initiates Biodesix at Buy With $32 Price Target
Roth Capital has initiated coverage on Biodesix (BDSX) with a "Buy" rating and set a price target of $32.00, according to a report published on June 25, 2026. This positive outlook follows a previous "Buy" initiation by HC Wainwright on June 15, 2026, with a $26.00 price target.
- Tone
- Positive 72/100
- Event
- Analyst action
- Published
- 25 Jun 2026 11:40
- Source
- marketscreener.com
Moomoo
Direct company coverage
Biodesix | SCHEDULE 13G/A: Others
This article provides a document link for Biodesix's SCHEDULE 13G/A filing, categorized under "Others." The content directly links to the official filing, giving access to information about significant ownership stakes in the company.
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 25 Jun 2026 07:10
- Source
- Moomoo
TradingKey
Direct company coverage
Biodesix Inc (BDSX) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Biodesix Inc (BDSX), focusing on its price momentum, support, and resistance levels. It details various technical indicators like MACD, RSI, and Moving Averages, which currently suggest a "Buy" signal for the stock. The article rates
- Tone
- Positive 82/100
- Event
- Macro sensitivity
- Published
- 22 Jun 2026 18:10
- Source
- TradingKey
Market source
Direct company coverage
Biodesix (BDSX) Surges 10.5%: Is This an Indication of Further Gains?
Biodesix (BDSX) shares increased by 10.5% due to strong investor optimism after Canaccord Genuity raised its price target from $22.00 to $27.00, maintaining a "Buy" rating. The company also made progress in its top-line growth, operational efficiency, and pipeline advancement in
- Tone
- Positive 73/100
- Event
- Analyst action
- Published
- 19 Jun 2026 12:27
- Source
- Market source
Stock Titan
Direct company coverage
Soleus discloses 525,241-share (5.1%) stake in Biodesix (BDSX)
Soleus Capital Master Fund, L.P. and its affiliated entities have reported a 5.1% beneficial ownership stake in Biodesix (BDSX), totaling 525,241 shares. This disclosure was made via a Schedule 13G SEC filing, indicating a passive investment. The percentage is based on 10,355,809
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 18 Jun 2026 20:47
- Source
- Stock Titan
Investing.com
Direct company coverage
Canaccord raises Biodesix stock price target to $27 on growth outlook
Canaccord Genuity increased its price target for Biodesix Inc. (NASDAQ:BDSX) shares to $27 from $22, maintaining a Buy rating, citing increased cash flow estimates and competitive positioning. The company reported strong Q1 2026 revenue growth of 42% and raised full-year guidance
- Tone
- Positive 82/100
- Event
- Guidance
- Published
- 18 Jun 2026 11:39
- Source
- Investing.com
TradingKey
Direct company coverage
Biodesix Inc (BDSX) Financial Health: Profitability & Balance Sheet Analysis
Biodesix Inc (BDSX) currently holds a financial score of 7.13, placing it in the weaker category within the Healthcare Providers & Services industry, despite average operating efficiency. The company recently reported a 42.30% year-over-year increase in quarterly revenue, reachin
- Tone
- Positive 58/100
- Event
- Earnings
- Published
- 17 Jun 2026 20:39
- Source
- TradingKey
TradingKey
Direct company coverage
Biodesix Inc (BDSX) Earnings Forecast: Future EPS & Revenue Growth Estimates
Biodesix Inc (BDSX) has an earnings forecast score of 8.40, placing it 18th in the Healthcare Providers & Services industry. Analysts have a consensus price target of $35.00, with a "Buy" rating from most surveyed analysts. The company's expected revenue for the next quarter is $
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 17 Jun 2026 18:39
- Source
- TradingKey
TradingKey
Direct company coverage
Biodesix Inc (BDSX) Valuation: PE, PB & Fair Value Analysis
The article provides a valuation analysis of Biodesix Inc (BDSX), noting its current valuation score of 8.53, ranking 36 out of 76 in the Healthcare Providers & Services industry. It highlights the company's current P/E ratio of -4.24, which is significantly below its recent high
- Tone
- Positive 64/100
- Event
- Market update
- Published
- 17 Jun 2026 17:09
- Source
- TradingKey
Intellectia AI
Direct company coverage
BDSX Technical Analysis & Stock Price Forecast
The article provides a technical analysis of Biodesix Inc (BDSX), indicating a "Strong Buy" consensus based on various technical indicators. Key metrics like MACD, Moving Averages, and Support/Resistance levels are analyzed, with BDSX currently trading above its 200-day moving av
- Tone
- Positive 81/100
- Event
- Guidance
- Published
- 17 Jun 2026 04:11
- Source
- Intellectia AI
TradingKey
Direct company coverage
Biodesix Inc (BDSX) Institutional Confidence
Biodesix Inc (BDSX) has an institutional shareholding score of 3.00, placing it 56th out of 76 in the Healthcare Providers & Services industry. The latest institutional shareholding proportion is 29.99%, showing a 17.90% decrease quarter-over-quarter. James Simons is identified a
- Tone
- Positive 65/100
- Event
- Market update
- Published
- 16 Jun 2026 15:11
- Source
- TradingKey
MT Newswires
Direct company coverage
HC Wainwright Initiates Biodesix at Buy With $26 Price Target
- Tone
- Positive 58/100
- Event
- Analyst action
- Published
- 15 Jun 2026 10:27
- Source
- MT Newswires
GuruFocus
Direct company coverage
BDSX Initiates Coverage On HC Wainwright & Co. -- Rating Set to Buy
HC Wainwright & Co. has initiated coverage on Biodesix (BDSX) with a Buy rating and a price target of $26.00. GuruFocus assesses BDSX as undervalued by 28.3% with a GF Value™ of $20.99, indicating a potential investment opportunity despite concerns regarding the company's financi
- Tone
- Positive 75/100
- Event
- Analyst action
- Published
- 15 Jun 2026 10:39
- Source
- GuruFocus
Market source
Direct company coverage
Are Medical Stocks Lagging Biodesix (BDSX) This Year?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 Jun 2026 07:00
- Source
- Market source
MSN
Direct company coverage
Biodesix, Inc. (BDSX) reports Q1 loss, tops revenue estimates
Biodesix, Inc. (BDSX) reported a narrower-than-expected loss in Q1, exceeding revenue estimates. The company posted a loss of $0.18 per share, which was better than the Zacks Consensus Estimate of a $0.23 loss per share. Revenue for the quarter reached $11.4 million, surpassing t
- Tone
- Positive 63/100
- Event
- Earnings
- Published
- 11 Jun 2026 14:08
- Source
- MSN
Zacks
Direct company coverage
Zacks Industry Outlook Highlights BrightSpring Health Services, Biodesix and HealthEquity
- Tone
- Neutral 50/100
- Event
- Guidance
- Published
- 09 Jun 2026 11:16
- Source
- Zacks
Finviz
Direct company coverage
BDSX - Biodesix Inc Stock Price and Quote
This article provides a detailed stock overview for Biodesix Inc (BDSX), including its latest closing price, financial metrics, insider transactions, and recent news. It also lists analyst ratings and their corresponding price targets and actions for the company. The content high
- Tone
- Neutral 50/100
- Event
- Analyst action
- Published
- 05 Jun 2026 11:09
- Source
- Finviz
Stock Titan
Direct company coverage
[EFFECT] BIODESIX INC SEC Filing
This article reports on a recent SEC filing for Biodesix Inc. (NASDAQ: BDSX), specifically an EFFECT filing. The filing indicates an effectiveness date of May 29, 2026, for a Form S-3 (Shelf Registration Statement), with a CIK of 0001439725. The company's stock overview, market d
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 01 Jun 2026 10:39
- Source
- Stock Titan
Stock Titan
Direct company coverage
Biodesix (NASDAQ: BDSX) registers resale of 375,000 shares
Biodesix, Inc. (NASDAQ: BDSX) has filed a prospectus to register the resale of up to 375,000 shares of its common stock by the selling stockholder, Perceptive Credit Holdings IV, LP. These shares are issuable upon the exercise of specific warrant certificates, and the registratio
- Tone
- Neutral 50/100
- Event
- Balance sheet
- Published
- 30 May 2026 20:39
- Source
- Stock Titan